- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Bombay HC restrains firm from infringing Sun Pharma trademark Prolomet
Overview
The Bombay High Court has noted an ad-interim injunction restraining the Salud Care (India) Private from using trademark PROLOMEK or any other trademark that is identical with or deceptively or confusingly similar to Sun Pharma Laboratories Ltd's mark PROLOMET.
The order was issued during a hearing conducted by G S Patel through video conferencing, deliberating the case filed by Sun Pharma. The counsel for Sun Pharma informed the court that in April 2021, Sun Pharma learned that Salud Care (India) Private markets a pharmaceutical preparation for the treatment of hypertension with tachycardia, angina, hyperthyroidism, and myocardial infarction with the same based drug, Metoprolol Succinate, under the trade mark PROLOMEK.
For more details, check out the full story on the link below:
Bombay HC Restrains Firm From Infringing Sun Pharma Trademark Prolomet